ROR1 and colorectal adenocarcinoma: In this study, we selected ROR1 as the target antigen primarily due to its established expression in colorectal adenocarcinomas and its emerging relevance in solid‐tumor‐targeted CAR T‐cell therapies.[35] We acknowledge, however, that ROR1 expression is not entirely restricted to tumor cells in our model, as evidenced by our observation of comparable ROR1 expression levels in HUVECs used within the IAC model.